Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Med Decis Making. 2018 Apr;38(1_suppl):126S-139S. doi: 10.1177/0272989X17729358.
Ductal carcinoma in situ (DCIS) can be a precursor to invasive breast cancer. Since the advent of screening mammography in the 1980's, the incidence of DCIS has increased dramatically. The value of screen detection and treatment of DCIS, however, is a matter of controversy, as it is unclear the extent to which detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other modeling approaches reported in the literature.
Five of the 6 CISNET models currently include DCIS. Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data sources used to estimate the DCIS model parameters.
These model differences translate into variation in outcomes, such as the amount of overdiagnosis of DCIS, with estimates ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The other models described in the literature also report a large range in outcomes, with progression rates varying from 20% to 91%.
DCIS grade was not yet included in the CISNET models.
In the future, DCIS data by grade from active surveillance trials, the development of predictive markers of progression probability, and evidence from other screening modalities, such as tomosynthesis, may be used to inform and improve the models' representation of DCIS, and might lead to convergence of the model estimates. Until then, the CISNET model results consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety and value of observational trials for low-risk DCIS.
导管原位癌(DCIS)可能是浸润性乳腺癌的前身。自 20 世纪 80 年代筛查性乳房 X 光检查问世以来,DCIS 的发病率急剧上升。然而,筛查和治疗 DCIS 的价值存在争议,因为尚不清楚检测和治疗 DCIS 在多大程度上可以预防浸润性疾病和降低乳腺癌死亡率。本文旨在概述癌症干预和监测建模网络(CISNET)目前用于 DCIS 自然史的建模方法,并将这些方法与文献中报告的其他建模方法进行比较。
CISNET 目前的 6 个模型中有 5 个包含 DCIS。大多数模型假设某些病变但不是全部病变会进展为浸润性癌。DCIS 的自然史无法直接观察,CISNET 模型在假设和用于估计 DCIS 模型参数的数据来源方面存在差异。
这些模型差异导致结果的差异,例如 DCIS 的过度诊断量,从 50 岁到 74 岁每两年筛查一次的估计值范围为 34%至 72%。文献中描述的其他模型也报告了结果的很大差异,进展率从 20%到 91%不等。
CISNET 模型中尚未包含 DCIS 分级。
未来,来自主动监测试验的 DCIS 分级数据、预测进展概率的预测标志物的发展以及其他筛查方式(如断层合成)的证据,可能会被用于告知和改进模型对 DCIS 的代表性,并可能导致模型估计的收敛。在那之前,CISNET 模型的结果一致显示出相当数量的 DCIS 过度诊断,支持低风险 DCIS 的观察性试验的安全性和价值。